Read about newest GLP-1 Retatrutide - Is Wegovy (Semaglutide) or Zepbound (Tirzepatide) right for you? Learn More
red measuring tape with orange pills in hand

WHAT IS SERMORELIN?

Sermorelin is a peptide which contains a total of 29 amino acids whose primary function is to encourage the pituitary gland to naturally produce more Human Growth Hormone (HGH).  It an analogue of growth hormone-releasing hormone, which means it binds to the growth hormone-releasing hormone receptor of the anterior pituitary gland and stimulateshe secretion of growth hormone. Sermorelin is often combined with other peptides like Ipamorelin which are growth hormone releasing peptides (also known as growth-releasing factor).  This combination, when administered via daily injections, will encourage your pituitary gland to secrete HGH at a much higher rate.

Screenshot 2024-08-13 at 2.14.39 PM

Sermorelin and HGH

In order to fully understand how Sermorelin works, it is important to understand how HGH works and what the HGH benefits are.  HGH is secreted by our pituitary glands every night while we sleep. The primary function of HGH is to help control the reproduction and growth of our cells and organs. As we age, our body's natural human growth hormone output decreases after peaking in our mid 20's. By the time we are in our 40's, our HGH levels diminish by 40% of what it was at age 20 and as we continue to age, those HGH levels continue to decrease dramatically.  In order to regain those youthful HGH levels, your pituitary glands need to be stimulated to begin production of HGH again. This can be done with Sermorelin. Sermorelin alone or combined with Ipamorelin is a safe and effective way to stimulate and increase your body's human growth hormone (HGH) production. 

Sermorelin Therapy

Sermorelin therapy consists of daily/nightly injections of Sermorelin which stimulates the pituitary gland to produce increased natural secretion of human growth hormone or HGH.

The approved medical use for this prescription drug is to increase growth hormone levels in children who have growth hormone deficiency. The medical use of Sermorelin in adults with low levels of the human growth hormone is an unlabeled medical use of the drug to obtain the treatment benefits described on this page. Although not specifically approved for increasing growth hormone levels in adults, prescribing Sermorelin for adults who have growth hormone deficiency is legally permissible and within the discretion of the treating physician. Since Sermorelin acetate is approved as safe for use in children to increase their production of growth hormone, it is considered safe for use in increasing the natural production of growth hormone in adults with suboptimal growth hormone.

Benefits of Sermorelin

Benefits come from healthy HGH levels, these include:

  • Increased growth hormone secretion and IGF-1 Levels with no increase in prolactin
  • Increased Body Weight and Length through increased protein synthesis
  • Increased Muscle Growth
  • Increased Bone Density
  • Improved Immune Function
  • Improved Cognition and Memory
  • Increased Collagen Production
  • Increased Fat Loss
  • Increased Cellular Repair and Regeneration

All patients always work directly with Dr. Bird to ensure patient safety and confidentiality. Call 480-839-4131 for a consultation regarding Sermorelin or Human Growth Hormone Therapy.

Visit the following pages for more on Sermorelin and Growth Hormone Therapy:

Research

Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.

Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.

R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728–9739, Mar. 2015.

Menaka C. Thounaojam, Folami L. Powell, Sagar Patel, Diana R. Gutsaeva, Amany Tawfik, Sylvia B. Smith, Julian Nussbaum, Norman L. Block, Pamela M. Martin, Andrew V. Schally, Manuela Bartoli Proc Natl Acad Sci U S A. 2017 Dec 12; 114(50): 13248–13253. Published online 2017 Nov 27. doi: 10.1073/pnas.1718592114
 
Tengjiao Cui, Joaquin J. Jimenez, Norman L. Block, Evangelos V. Badiavas, Luis Rodriguez-Menocal, Ailin Vila Granda, Renzhi Cai, Wei Sha, Marta Zarandi, Roberto Perez, Andrew V. Schally Oncotarget. 2016 Aug 16; 7(33): 52661–52672. Published online 2016 Aug 2. doi: 10.18632/oncotarget.11024

Contact Us